NexImmune (NEXI) Stock Forecast, Price Target & Predictions
NEXI Stock Forecast
NexImmune stock forecast is as follows: an average price target of $3.33 (represents a 1156.13% upside from NEXI’s last price of $0.27) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
NEXI Price Target
The average price target for NexImmune (NEXI) is $3.33 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $2.00. This represents a potential 1156.13% upside from NEXI's last price of $0.27.
NEXI Analyst Ratings
According to 4 Wall Street analysts, NexImmune's rating consensus is 'Buy'. The analyst rating breakdown for NEXI stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 2 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
NexImmune Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 16, 2022 | - | Barclays | $2.00 | $1.19 | 68.11% | 654.43% |
| Aug 16, 2022 | - | Raymond James | $3.00 | $1.26 | 138.10% | 1031.65% |
| Jun 01, 2022 | - | BTIG | $5.00 | $2.28 | 119.30% | 1786.08% |
The latest NexImmune stock forecast, released on Aug 16, 2022 by Barclays company, set a price target of $2.00, which represents a 68.11% increase from the stock price at the time of the forecast ($1.19), and a 654.43% increase from NEXI last price ($0.27).
NexImmune Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.27 | $0.27 | $0.27 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of NexImmune stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NexImmune's last price of $0.27. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 16, 2022 | Cantor Fitzgerald | - | Neutral | Downgrade |
| Nov 15, 2022 | Raymond James | Outperform | Market Perform | Downgrade |
| Aug 16, 2022 | Barclays | Overweight | Overweight | Hold |
| Aug 16, 2022 | Raymond James | Outperform | Outperform | Hold |
| Jun 01, 2022 | BTIG | - | Buy | Initialise |
| Feb 22, 2022 | Raymond James | Outperform | Outperform | Hold |
NexImmune's last stock rating was published by Cantor Fitzgerald on Nov 16, 2022. The company Downgrade its NEXI rating from "null" to "Neutral".
NexImmune Financial Forecast
NexImmune Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| # Analysts | - | - | - |
| Surprise % | - | - | - |
NexImmune's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NEXI's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
NexImmune EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EBITDA | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
undefined analysts predict NEXI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than NexImmune's previous annual EBITDA (undefined) of $NaN.
NexImmune Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| Net Income | - | - | - |
| Avg Forecast | $-510.75K | $-524.55K | $-731.61K |
| High Forecast | $-510.75K | $-524.55K | $-731.61K |
| Low Forecast | $-510.75K | $-524.55K | $-731.61K |
| Surprise % | - | - | - |
NexImmune's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NEXI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
NexImmune SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| SG&A | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
NexImmune's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NEXI last annual SG&A of $NaN (undefined).
NexImmune EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EPS | - | - | - |
| Avg Forecast | $-0.37 | $-0.38 | $-0.53 |
| High Forecast | $-0.37 | $-0.38 | $-0.53 |
| Low Forecast | $-0.37 | $-0.38 | $-0.53 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, NexImmune's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NEXI previous annual EPS of $NaN (undefined).
NexImmune Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.05 | $5.50 | 10900.00% | Buy |
| NEXI | NexImmune | $0.27 | $3.33 | 1133.33% | Buy |
| IMMX | Immix Biopharma | $1.81 | $7.00 | 286.74% | Buy |
| CNSP | CNS Pharmaceuticals | $0.15 | $0.50 | 233.33% | - |
| PDSB | PDS Bio | $3.12 | $9.00 | 188.46% | Buy |
| INZY | Inozyme Pharma | $5.83 | $14.67 | 151.63% | Buy |
| MREO | Mereo BioPharma Group | $3.95 | $6.75 | 70.89% | Buy |
| TERN | Terns Pharmaceuticals | $9.63 | $14.25 | 47.98% | Buy |
| ZURA | Zura Bio | $3.88 | $5.00 | 28.87% | Buy |
| XBIO | Xenetic Biosciences | $3.70 | $4.00 | 8.11% | - |
| HOOK | HOOKIPA Pharma | $4.78 | $3.00 | -37.24% | Buy |
| PALI | Palisade Bio | $4.08 | $1.50 | -63.24% | Buy |
NEXI Forecast FAQ
Is NexImmune a good buy?
Yes, according to 4 Wall Street analysts, NexImmune (NEXI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 50.00% of NEXI's total ratings.
What is NEXI's price target?
NexImmune (NEXI) average price target is $3.33 with a range of $2 to $5, implying a 1156.13% from its last price of $0.265. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will NexImmune stock go up soon?
According to Wall Street analysts' prediction for NEXI stock, the company can go up by 1156.13% (from the last price of $0.265 to the average price target of $3.33), up by 1786.08% based on the highest stock price target, and up by 654.43% based on the lowest stock price target.
Can NexImmune stock reach $0?
NEXI's average twelve months analyst stock price target of $3.33 supports the claim that NexImmune can reach $0 in the near future.
What are NexImmune's analysts' financial forecasts?
NEXI's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-1.767M (high $-1.767M, low $-1.767M), average SG&A $0 (high $0, low $0), and average EPS is $-1.28 (high $-1.28, low $-1.28).